Evolet Healthcare Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Evolet Healthcare Private Limited Pharmaceutical Export Portfolio Dataset — 2 Products, $203.2K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Evolet Healthcare Private Limited — Pharmaceutical Exporter Profile (2026) | 2 Products, $203.2K Trade | TransData Nexus

Evolet Healthcare Private Limited

Indian Pharmaceutical Exporter · Advanced Antibiotics Specialist · $203.2K Total Trade · DGFT Verified

Evolet Healthcare Private Limited is an Indian pharmaceutical exporter with a total trade value of $203.2K across 2 products in 2 therapeutic categories. Based on 9 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Ceftazidime ($168.5K), Streptomycin ($34.6K), .

Evolet Healthcare Private Limited — Export Portfolio & Destination Treemap

Evolet Healthcare Private Limited pharmaceutical export portfolio — 2 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Evolet Healthcare Private Limited? — Company Overview & Market Position

Evolet Healthcare Private Limited, established on February 7, 2011, is a privately held pharmaceutical company headquartered in Bhorakalan, Haryana, India. The company is registered under the Corporate Identification Number (CIN) U33100DL2011PTC213448. As of the latest available data, Evolet Healthcare has an authorized capital of ₹38.50 crore and a paid-up capital of ₹36.19 crore. The company employs approximately 43 professionals. Evolet Healthcare specializes in the manufacturing and export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Their product portfolio is concentrated in the antibiotic segment, with a focus on advanced antibiotics.

What Does Evolet Healthcare Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Ceftazidime$168.5K 2Streptomycin$34.6K

Evolet Healthcare Private Limited Therapeutic Categories — 2 Specializations

Product Portfolio — Top 2 by Export Value

Evolet Healthcare Private Limited exports 2 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Ceftazidime	Advanced Antibiotics	$168.5K	6	1.6%	11
2	Streptomycin	Antibiotics	$34.6K	3	6.0%	5

Evolet Healthcare Private Limited exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $203.2K. The top category is Advanced Antibiotics (82.9% of portfolio), followed by Antibiotics (17.1%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Evolet Healthcare Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Evolet Healthcare operates manufacturing facilities in India, with a registered address at 1101-1108, 11th Floor, Imperia Mindspace, Golf Course Extension Road, Near Village Maidawas, Sector 62, Bhorakalan, Haryana, 122413. The company has expanded its manufacturing capabilities to include a new line in India as of 2016. Specific details regarding the capacities and specializations of these facilities are not publicly disclosed.

3Key Leadership

The leadership team at Evolet Healthcare includes:

Zafarkhon Mirzoev: Director, appointed on February 7, 2011.

Khayrullo Avgonov: Director, appointed on August 3, 2012.

Sadullo Abdulloev: Director, appointed on February 7, 2011.

Aman Preet Kaur: Company Secretary, appointed on September 1, 2022.

These individuals play pivotal roles in steering the company's strategic direction and operations.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Evolet Healthcare Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Evolet Healthcare's export activities, as per TransData Nexus proprietary trade data from 2022 to 2026, include a total export value of $203,000 USD across 9 shipments, with products spanning two therapeutic categories. The top two products exported are Ceftazidime, with a value of $169,000 USD and a market share of 1.6%, and Streptomycin, valued at $35,000 USD with a market share of 6.0%. The primary therapeutic focus is on advanced antibiotics, accounting for 82.9% of the portfolio, while antibiotics constitute 17.1%. Notably, Evolet Healthcare does not hold a market leader position in any specific category. The company's portfolio is highly concentrated, with the top five products comprising 100% of the export value.

2Emerging Markets

Evolet Healthcare has made strategic inroads into emerging markets, particularly in Africa, Latin America, and Southeast Asia. The company's expansion into these regions is facilitated by its adherence to international quality standards, including WHO prequalification, which enhances its credibility and access to these markets. By aligning with global health regulations, Evolet Healthcare positions itself as a reliable supplier in these growing pharmaceutical markets.

3Geographic Strategy

Evolet Healthcare Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Evolet Healthcare's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The company has not disclosed information about its interactions with the U.S. Food and Drug Administration (FDA), which is a critical aspect for market access in the United States. Without this information, it is challenging to assess the company's compliance with FDA regulations and its ability to market products in the U.S.

2WHO & EU GMP

Evolet Healthcare's adherence to international quality standards, such as WHO prequalification and EU Good Manufacturing Practice (GMP) certifications, is not explicitly detailed in the available sources. These certifications are essential for ensuring product quality and safety, particularly for markets that require compliance with stringent regulatory standards. The absence of publicly available information on these certifications may impact the company's ability to access certain international markets that mandate such compliance.

3CDSCO & Indian Regulatory

Evolet Healthcare Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Evolet Healthcare operates in a competitive pharmaceutical market, particularly in the antibiotic segment. While specific competitors are not identified in the available data, the company's focus on advanced antibiotics positions it in direct competition with other pharmaceutical companies specializing in this therapeutic area. The company's market share in its top products—Ceftazidime at 1.6% and Streptomycin at 6.0%—indicates a modest presence in the global market. To enhance its competitive position, Evolet Healthcare may consider expanding its product portfolio and exploring new therapeutic areas.

2Key Differentiators

Evolet Healthcare's key differentiators include its specialization in advanced antibiotics and its strategic expansion into emerging markets. The company's adherence to international quality standards, such as WHO prequalification, enhances its credibility in global markets. However, the high concentration of its export portfolio in a limited number of products suggests a need for diversification to strengthen its market position.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Evolet Healthcare Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Evolet Healthcare's track record in the pharmaceutical industry is characterized by its focus on high-quality antibiotic formulations and its expansion into international markets. The company's export volume, though modest, reflects a consistent approach to international trade. Reliability indicators, such as adherence to international quality standards and regulatory compliance, are essential for assessing the company's suitability as a supplier. The lack of detailed information on regulatory approvals and certifications may pose challenges for potential partners in evaluating the company's reliability.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

FDA Facility Registration: Confirm the company's registration with the U.S. Food and Drug Administration to assess eligibility for the U.S. market.

WHO-GMP Certification: Verify the company's adherence to World Health Organization Good Manufacturing Practice standards to ensure product quality.

Frequently Asked Questions — Evolet Healthcare Private Limited

How many pharmaceutical products does Evolet Healthcare Private Limited export from India?

Evolet Healthcare Private Limited exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Ceftazidime ($168.5K), Streptomycin ($34.6K). Total export value is $203.2K.

What is Evolet Healthcare Private Limited's total pharmaceutical export value?

Evolet Healthcare Private Limited's total pharmaceutical export value is $203.2K, based on 9 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Evolet Healthcare Private Limited cover?

Evolet Healthcare Private Limited exports across 2 therapeutic categories. The largest are Advanced Antibiotics (82.9%, 1 products), Antibiotics (17.1%, 1 products).

Get Full Evolet Healthcare Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.